| Literature DB >> 25769721 |
Jing Zhang1, Jingjing Jiao1, Silvia Cermelli2, Kyle Muir2, Kwang Hwa Jung1, Ruhai Zou3, Asif Rashid4, Mihai Gagea5, Sonya Zabludoff6, Raghu Kalluri7, Laura Beretta8.
Abstract
miR-21 is upregulated in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, where it is associated with poor prognosis. Here, we offer preclinical evidence that miR-21 offers a therapeutic and chemopreventive target in these liver cancers. In mice with hepatic deletion of Pten, anti-miR-21 treatment reduced liver tumor growth and prevented tumor development. These effects were accompanied with a decrease in liver fibrosis and a concomitant reduction of CD24(+) liver progenitor cells and S100A4(+) cancer-associated stromal cells. Notch2 inhibition also occurred in tumors following anti-miR-21 treatment. We further showed that miR-21 is necessary for the survival of CD24(+) progenitor cells, a cellular phenotype mediated by Notch2, osteopontin, and integrin αv. Our results identify miR-21 as a key regulator of tumor-initiating cell survival, malignant development, and growth in liver cancer, highlighting the role of CD24(+) cells in the expansion of S100A4(+) cancer-associated stromal cells and associated liver fibrosis. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25769721 PMCID: PMC4603420 DOI: 10.1158/0008-5472.CAN-14-1254
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701